SME Times is powered by   
Search News
Just in:   • SpiceJet re-introduces 'Zero Change fee' offer  • 'Good' progress made at nuclear talks but issues remain: Iran  • Fiscal package may be on cards to maintain economic recovery amid Covid 2.0  • Striking taxi drivers demands unreasonable: Goa tourism body  • Govt notifies Rs 6k cr PLI scheme for AC, LED light manufacturing 
Last updated: 20 Jun, 2017  

cadila.thumb.jpg Zydus Cadila gets USFDA nod for migraine drug

cadila.jpg
   Top Stories
» Fiscal package may be on cards to maintain economic recovery amid Covid 2.0
» FICCI writes to 25 CMs on Covid management
» Regulation of insolvent firms' shares still remains a dilemma
» ECLGS 2.0 now covers SMA-1 borrowers
» Forex reserves up by over $4 bn
SME Times News Bureau | 20 Jun, 2017
Pharma major Zydus Cadila on Monday said it has received the final approval from the US Food and Drug Administration (FDA) to sell Eletriptan Hydrobromide tablets, used in the treatment of migraine.

According to the company, the drug with strengths 20mg and 40mg will be produced at the group's formulations manufacturing facility at the Pharma SEZ (special economic zone) in Ahmedabad.

"The group now has more than 120 approvals and has so far filed over 300 ANDAs (abbreviated new drug applications ) since the commencement of the filing process in FY 2003-04," the firm said in a regulatory filing with the BSE. 
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 18 Apr, 2021
  Daily Poll
COVID-19 has directly affected your business
 Yes
 No
 Can't say
  Commented Stories
» Covid second wave: Lockdown or no lockdown(2)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter